Financial Performance - The company's operating revenue for Q3 2024 reached ¥89,552,626.84, representing a year-on-year increase of 137.26%[2] - The net profit attributable to shareholders for Q3 2024 was -¥6,489,699.32, with a year-to-date net profit of -¥46,889,888.23[2] - The basic earnings per share for Q3 2024 was -¥0.01, and the diluted earnings per share was also -¥0.01[3] - The company achieved a year-to-date operating revenue increase of 53.34%, driven by enhanced product promotion and channel utilization[6] - Total operating revenue for the first three quarters of 2024 reached ¥231,030,545.43, a significant increase of 53.3% compared to ¥150,665,541.41 in the same period of 2023[19] - The company reported a net loss of ¥46,889,888.23 for the first three quarters of 2024, an improvement from a net loss of ¥96,582,500.85 in the same period of 2023[21] - Operating profit (loss) improved to -¥52,997,337.55 from -¥93,993,126.65 year-over-year[21] - Basic and diluted earnings per share improved to -¥0.07 from -¥0.13 year-over-year[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,205,651,919.73, a decrease of 25.79% compared to the end of the previous year[3] - The total assets decreased to ¥1,205,651,919.73 from ¥1,624,560,125.88, a decline of 25.7%[18] - The company’s equity attributable to shareholders decreased by 8.09% year-on-year, totaling ¥855,722,332.04[3] - The total liabilities decreased to ¥349,929,587.69 from ¥693,517,978.39, a reduction of 49.6%[18] - Current assets totaled RMB 495,170,740.50, down from RMB 881,533,254.03 in the previous period, indicating a significant reduction[16] - Non-current assets totaled RMB 710,481,179.23, down from RMB 743,026,871.85, indicating a decrease of about 4%[17] Cash Flow - The company reported a net cash flow from operating activities of -¥64,056,674.63 for the year-to-date period[3] - The net cash flow from operating activities for the first three quarters of 2024 was -64,056,674.63 RMB, compared to -21,150,724.69 RMB in the same period of 2023, indicating a decline in operational cash flow[25] - Total cash inflow from operating activities decreased to 211,980,745.20 RMB in 2024 from 260,896,973.39 RMB in 2023, reflecting a year-over-year decline of approximately 18.7%[25] - Cash outflow from operating activities was 276,037,419.83 RMB in 2024, slightly down from 282,047,698.08 RMB in 2023, showing a decrease of about 2.5%[25] - The company reported a significant reduction in cash flow from operations, impacting liquidity and operational flexibility[16] Investments and Financing - The company received government subsidies amounting to ¥14,483,829.44 year-to-date, which positively impacted its financial performance[4] - Cash inflow from investment activities was 196,544,899.48 RMB in 2024, significantly lower than 599,270,726.35 RMB in 2023, representing a decline of approximately 67.2%[25] - The net cash flow from investment activities improved to 185,104,669.99 RMB in 2024, compared to -89,657,920.92 RMB in 2023, indicating a positive turnaround[25] - Cash inflow from financing activities was 222,004,918.60 RMB in 2024, up from 118,646,944.44 RMB in 2023, marking an increase of approximately 87.2%[25] - The net cash flow from financing activities was -314,288,040.40 RMB in 2024, worsening from -4,127,640.96 RMB in 2023, indicating increased financial strain[25] Operational Changes - The company is actively seeking CMO orders to maximize production capacity and reduce costs[7] - There were no new product launches or major strategic initiatives mentioned during the earnings call, indicating a focus on financial restructuring and cost management[16] - Research and development expenses decreased to ¥14,987,666.90, down 29.5% from ¥21,226,696.58 in the previous year[19] - The company reported a significant increase in cash paid for purchasing goods and services, rising to 145,189,289.44 RMB in 2024 from 107,302,510.84 RMB in 2023, an increase of approximately 35.3%[25] - Cash paid for employee compensation decreased to 36,462,803.02 RMB in 2024 from 41,659,416.41 RMB in 2023, reflecting a decrease of about 12.0%[25]

| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2024-071 | | --- | --- | --- | | 债券代码：113610 | 证券简称：灵康转债 | | 灵康药业集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （三）根据《上海证券交易所股票上市规则》等相关规定以及《灵康药业集 团股份有限公司公开发行可转换公司债券募集说明书》（以下简称"募集说明书"） 的有关约定，公司该次发行的"灵康转债"自 2021 年 6 月 7 日起可转换为本公 司 A 股普通股股票，目前转股价格为 8.00 元/股。 1 （四）因"灵康转债"触发《灵康药业集团股份有限公司公开发行可转换公 司债券募集说明书》中约定的回售条款，公司于 2024 年 6 月 24 日至 2024 年 6 月 28 日进行了回售，回售数量为 2,048,260 张，回售资金已于 2024 年 7 月 3 日 发放。 二、可转债本次转股情况 "灵康转债"自 2024 年 7 ...

证券代码：603669 证券简称：灵康药业 公告编号：2024-069 灵康药业集团股份有限公司 关于控股股东股票质押式回购交易延期购回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至公告披露日，公司控股股东灵康控股集团有限公司（以下简称"灵 康控股"）直接及间接持有公司股份 33,965.28 万股无限售流通股股票，占公司 总股本的 47.09%，灵康控股累计质押公司股票数量为 10,482.96 万股，占其持 有公司股份总数的 30.86%，占公司总股本的 14.53%。 2、本次延期购回的股份不存在用作重大资产重组业绩补偿等事项的担保或 其他保障用途等情况。 3、控股股东及其一致行动人累计质押股份情况 截至目前，灵康控股所持股份的质押风险可控，不存在引发平仓或被强 制平仓的风险。 2024 年 9 月 24 日，灵康药业集团股份有限公司（以下简称"灵康药业"或 "本公司"）接到公司控股股东灵康控股关于股票质押式回购交易延期购回的通 知，现将相关情况公告如下： 一、本次股票质押式回购交易延 ...

截至公告披露日，公司控股股东灵康控股集团有限公司（以下简称"灵 康控股"）直接及间接持有公司股份 33,965.28 万股无限售流通股股票，占公司 总股本的 47.09%，灵康控股本次解除质押股份 2,000.00 万股,占其持有公司股 份总数的 5.89%，占公司总股本的 2.77%。 2024 年 9 月 24 日，灵康药业集团股份有限公司（以下简称"灵康药业"或 "本公司"）接到公司控股股东灵康控股关于部分股份解除质押的通知，现将相 关情况公告如下： | 股东名称 | 灵康控股 | | --- | --- | | 本次解除质押股份 | 2,000.00 万股 | | 占其所持股份比例 | 5.89% | | 占公司总股本比例 | 2.77% | | 解除质押时间 | 2024 年 9 月 20 日 | | 持股数量 | 33,965.28 万股 | | 持股比例 | 47.09% | | 剩余被质押股份数量 | 10,482.96 万股 | | 剩余被质押股份数量占其所持股份比例 | 30.86% | | 剩余被质押股份数量占公司总股本比例 | 14.53% | 经与灵康控股确认，解除质押的股份暂无后续 ...

注册分类：化学药品 证券代码：603669 证券简称：灵康药业 公告编号：2024-068 灵康药业集团股份有限公司 关于子公司左卡尼汀注射液 通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"或"灵康药业"）全资子公 司海南美兰史克制药有限公司（以下简称"美兰史克"）近日收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的关于"左卡尼汀注射液"（以下简 称"该药品"）《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致 性评价。现将有关情况公告如下： 一、药品基本情况 （一）药物名称：左卡尼汀注射液 剂型：注射剂 规格：5ml：1g 受理号：CYHB2350738 上市许可持有人：海南美兰史克制药有限公司 地址：海口市南海大道 168 号海口保税区 6 号路 生产企业：海南灵康制药有限公司 地址：海南省海口国家高新技术产业开发区药谷工业园药谷二横路 16 号 药品批准文号：国药准字 H20203512 审批结论：根据《中华人民共和国药品管 ...

证券代码：603669 证券简称：灵康药业 公告编号：2024-067 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"或"灵康药业"）全资子公 司海南灵康制药有限公司（以下简称"灵康制药"）近日收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的关于"注射用头孢唑肟钠"（以下简称 "该药品"）《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性 评价。现将有关情况公告如下： 一、药品基本情况 （一）药物名称：注射用头孢唑肟钠 剂型：注射剂 注册分类：化学药品 规格：0.5g（按 C₁₃H₁₃N₅O₅S₂计） 灵康药业集团股份有限公司 关于子公司注射用头孢唑肟钠 通过仿制药一致性评价的公告 注册分类：化学药品 规格：2.0g（按 C₁₃H₁₃N₅O₅S₂计） 受理号：CYHB2450194 上市许可持有人：海南灵康制药有限公司 地址：海南省海口国家高新技术产业开发区药谷工业园药谷二横路 16 号 生产企业：海南灵康制药有限公司 地址：海南省海口国家高新技术产业开发 ...

| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2024-066 | | --- | --- | --- | | 债券代码：113610 | 证券简称：灵康转债 | | 灵康药业集团股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"）于近日收到中信证券股份 有限公司（以下简称"中信证券"）出具的《中信证券股份有限公司关于更换灵 康药业集团股份有限公司公开发行可转换公司债券持续督导保荐代表人的函》， 具体情况如下： 2024 年 8 月 31 日 1 附：保荐代表人何康简历 何康先生，保荐代表人、非执业注册会计师、律师执业资格，硕士研究生学 历，具有 8 年以上投资银行工作经验，曾负责或参与：屹通新材、百华悦邦、华 塑科技、认养一头牛等 IPO 项目，以及开山股份非公开、灵康药业可转债、新安 股份资产重组、百隆东方非公开等再融资及重大资产重组项目。 2 中信证券作为公司公开发行可转换公司债券的保荐机构，指定向晓娟女士、 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：603669 证券简称：灵康药业 公告编号：2024-063 灵康药业集团股份有限公司 第四届董事会第十九次会议决议公告 具体内容详见同日披露于上海证券交易所网站上（www.sse.com.cn）的公告。 2、审议通过了《关于 2024 年半年度募集资金存放与实际使用情况的专项报 告的议案》 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票。 具体内容详见同日披露于上海证券交易所网站上（www.sse.com.cn）的公告。 特此公告。 灵康药业集团股份有限公司董事会 一、董事会会议召开情况 灵康药业集团股份有限公司（以下简称"公司"）第四届董事会第十九次会 议通知于 2024 年 8 月 17 日以电话、电子邮件等形式发出，会议于 2024 年 8 月 22 日在浙江灵康药业有限公司会议室以现场结合通讯方式召开。会议由董事长 陶灵萍召集并主持，应出席本次会议的董事 7 人，实际出席本次会议的董事 7 人。公司监事、高级管理人员列席了会议。本次会议的召集、 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥141,477,918.59, representing a 25.29% increase compared to ¥112,920,840.32 in the same period last year[14]. - The net profit attributable to shareholders of the listed company was -¥40,400,188.91, a 42.05% improvement from -¥69,721,337.36 in the previous year[14]. - The net profit after deducting non-recurring gains and losses was -¥54,418,620.81, which is a 25.65% increase compared to -¥73,190,592.85 last year[15]. - Basic earnings per share for the reporting period (January to June) was -0.06 RMB, improving by 40.00% compared to -0.10 RMB in the same period last year[16]. - Net profit attributable to shareholders decreased losses by 42.05% year-on-year, driven by increased promotion of centralized procurement products and effective cost control measures[17]. - Revenue increased by 25.29% year-on-year, attributed to enhanced promotion of centralized procurement products and effective market strategies[16]. Cash Flow and Assets - The net cash flow from operating activities was -¥38,201,983.95, a decrease of 47.91% from -¥25,827,138.30 in the previous year[15]. - The total assets at the end of the reporting period were ¥1,448,072,776.45, down 10.86% from ¥1,624,560,125.88 at the end of the previous year[15]. - The net assets attributable to shareholders of the listed company decreased by 4.52% to ¥888,993,048.87 from ¥931,042,147.49 at the end of the previous year[15]. - The company's cash and cash equivalents decreased from 343,418,554.46 RMB at the end of 2023 to 323,670,765.11 RMB by June 30, 2024[95]. - The total current assets decreased from 881,533,254.03 RMB at the end of 2023 to 725,113,933.72 RMB by June 30, 2024[95]. Investment and R&D - The company has increased its R&D investment, focusing on major disease areas such as oncology, liver disease, and cardiovascular diseases[22]. - The company has increased its R&D investment, with a focus on high-margin new products, and has several projects in the pipeline covering major disease areas like anti-infection and cardiovascular drugs[25]. - Research and development expenses for the first half of 2024 were ¥10,639,383.76, down from ¥13,301,203.59, a decrease of 20%[102]. Market and Competition - The pharmaceutical manufacturing industry in China achieved revenue of 1,235.27 billion RMB in the first half of 2024, a year-on-year decrease of 0.9%[22]. - The company faces risks from market competition affecting revenue due to centralized drug procurement policies[40]. - New product development carries inherent risks, including long cycles and high failure rates, despite the company having a mature R&D system[40]. Environmental Compliance - The company has implemented effective management of wastewater, waste gas, and noise emissions, meeting environmental protection standards[42]. - The company has maintained compliance with pollution discharge standards, with no exceedances reported in wastewater emissions[46]. - The company has successfully managed its pollutant emissions, with specific metrics showing no exceedances in key categories such as total nitrogen and total phosphorus[46]. Corporate Governance - The company did not distribute profits or increase capital reserves during the reporting period[3]. - The report is unaudited, and the management has confirmed the accuracy and completeness of the financial statements[3]. - The company has experienced changes in senior management, including the election of a new deputy general manager and a new supervisor[44]. Strategic Initiatives - The company has signed a strategic cooperation framework agreement with Laboratoire Bailly-Creat to expand international cooperation and explore overseas sales channels[28]. - The company is actively pursuing product consistency evaluations, with several products having passed the quality and efficacy consistency evaluation[27]. - The company is adapting to industry policy changes and enhancing its market presence in county hospitals and community clinics[20]. Financial Liabilities and Equity - The total amount of guarantees provided by the company, excluding those to subsidiaries, is RMB 8,978,661.20, which accounts for 1.01% of the company's net assets[72]. - The company has a comprehensive credit agreement with Everbright Bank Haikou Branch with a credit limit of RMB 100 million, valid from January 26, 2024, to January 25, 2027[74]. - The company reported a negative retained earnings of -216,321,655.18, compared to -175,921,466.27 in the previous period[97]. Social Responsibility - The company is committed to fulfilling its social responsibilities and supporting economic development, focusing on poverty alleviation, ecological protection, and job creation[57]. - The company invested over 4 million RMB in the white fungus industry rural revitalization project, constructing 50 smart container mushroom cultivation rooms in Jilin Village, which has already commenced production[57].

灵康药业集团股份有限公司 第四届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、 监事会会议召开情况 证券代码：603669 证券简称：灵康药业 公告编号：2024-064 （2）公司 2024 年半年度报告公允的反映了公司报告期内的财务状况和经营 成果，所包含的信息能从各个方面真实地反映出公司报告期内的经营管理和财务 状况等事项； 灵康药业集团股份有限公司（以下简称"公司"）第四届监事会第十五次会 议通知于 2024 年 8 月 17 日以电话、电子邮件等形式发出，会议于 2024 年 8 月 22 日在浙江灵康药业有限公司会议室以现场结合通讯方式召开。会议由监事会 主席陈彦先生召集并主持，会议应出席 3 人，实际出席 3 人。本次会议参与表决 人数及召集、召开程序符合《公司法》和《公司章程》的有关规定，会议形成的 决议合法有效。 二、监事会会议审议情况 经出席会议的监事讨论及表决，一致通过以下决议： 1、审议并通过了《2024 年半年度报告及摘要》 监事会对公司 2024 年半年度报告 ...